Balyasny Asset Management’s GSK GSK Stock Holding History

Balyasny Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-900,000	Closed	-$44M	–	1910
2018 Q1	$44M	Buy	+900,000	New	+$41.9M	0.18%	146

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Balyasny Asset Management's GSK Position: Q1 2026 in Review

Balyasny Asset Management sold out of GSK (GSK) in Q1 2026, closing a stake of 15,963 shares — an estimated $783K sold.

Balyasny Asset Management first reported a position in GSK in Q2 2013 and held it in 26 quarters. The position peaked at $72.5M in Q4 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Balyasny Asset Management reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 15,963 GSK shares in Q1 2026, an estimated $783K.
Balyasny Asset Management first reported a position in GSK in Q2 2013 and held it in 26 quarters.
Balyasny Asset Management's GSK position peaked at $72.5M in Q4 2022.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.